Advanced Oncotherapy - Issue of warrants

Advanced Oncotherapy

16/06/2023 18:23

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230616:nRSP0661Da&default-theme=true

RNS Number : 0661D  Advanced Oncotherapy PLC  16 June 2023

16 June 2023

 

ADVANCED ONCOTHERAPY PLC

 

("Advanced Oncotherapy" or the "Company")

 

Issue of Warrants

 

Further to the Company's announcement on 12 December 2022, Advanced
Oncotherapy (AIM:AVO), the developer of LIGHT, the next-generation proton
therapy system for cancer treatment, announces that it has, on 14 June 2023,
issued warrants to subscribe for 12,000,000 new Ordinary Shares. The warrants
were issued per the terms of the £1,500,000 equity subscription announced on
12 December 2022.

 

The warrants have an exercise price of 25 pence per share and are
exercisable until 15 December 2027.

 

The issue of warrants has been conducted under the Company's existing share
authorities and, notwithstanding the announcement made by the Company on 12
December 2022, the Company can confirm that it does not require to convene a
general meeting to put in place new share authorities for this warrant issue.

 

Following this issuance of warrants the Company has a total of 199,061,873
warrants in issue.

 

 

- ENDS -

 

 

 Advanced Oncotherapy plc                                    www.avoplc.com (http://www.avoplc.com/)
 Dr. Michael Sinclair, Executive Chairman                    Tel: +44 (0) 20 3617 8728
 Nicolas Serandour, CEO

 WH Ireland Limited (Financial adviser)                      Tel: +44 (0) 20 7220 1666
 Antonio Bossi / James Bavister                              AVOPLC@whirelandcm.com

 Allenby Capital Limited (Nomad and Joint Broker)
 Nick Athanas / Piers Shimwell (Corporate Finance)           Tel: +44 (0) 20 3328 5656

 Amrit Nahal / Matt Butlin (Sales & Corporate Broking)

 SI Capital Ltd (Joint Broker)
 Nick Emerson                                                Tel: +44 (0) 1483 413 500
 Jon Levinson                                                Tel: +44 (0) 20 3871 4066

 

Notes for Editors

 

About Advanced Oncotherapy Plc www.avoplc.com (http://www.avoplc.com/)

 

Advanced Oncotherapy, a UK headquartered company with offices
in London, Geneva, The Netherlands and in the USA, is a provider of
particle therapy with protons that harnesses the best in modern
technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on
the development of a proprietary proton accelerator called, Linac Image Guided
Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams
in a way that facilitates greater precision and electronic control.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that
will enable them to treat cancer with innovative technology as well as
expected lower treatment-related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging
improvements in delivering proton therapy and actively seeks working
relationships with providers of these innovative technologies. Through these
relationships, the Company will remain the prime provider of an innovative and
cost-effective system for particle therapy with protons.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEZZGMVNVMGFZM